Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMPT 314

Next Previous
X
Search
Drug Profile

IMPT 314

Alternative Names: CD19-CD20 bi-specific CAR-T - ImmPACT Bio; CD19-CD20 bi-specific chimeric antigen receptor-T cell therapy - ImmPACT Bio; IMPT-314

Latest Information Update: 22 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmPACT Bio
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma
  • Phase I Chronic lymphocytic leukaemia

Most Recent Events

  • 15 May 2023 IMPT 314 receives Fast Track designation for Non-Hodgkin's lymphoma [Parenteral] (Second-line therapy or greater) in USA
  • 09 May 2023 Phase-I/II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (Parenteral) (NCT05826535)
  • 08 May 2023 ImmPACT Bio plans to initiate phase I/II trial in B-cell lymphoma in USA in 2Q of 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top